Patents by Inventor Won Ki Kang

Won Ki Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gas sensor array having shared field effect transistor
    Patent number: 11921080
    Abstract: The gas sensor according to an exemplary embodiment of the present invention comprises: an FET device including one or more gate electrodes; a sensor array part including a plurality of sensors, in which a first electrode of each sensor is connected to at least one gate electrode of the plurality of gate electrodes in the FET device; and a controller detecting a gas using a current between a drain-source in response to voltage changes in the gate electrode of the FET device, wherein each sensor includes: a first electrode connected to a gate electrode of the FET device; a second electrode receiving an operating voltage through a switch controlled by the controller; and a detection film interposed between the first electrode and the second electrode.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: March 5, 2024
    Assignee: KOREA ELECTRONICS TECHNOLOGY INSTITUTE
    Inventors: Kook Nyung Lee, Woo Kyeong Seong, Won Hyo Kim, Dong Ki Hong, Hye Lim Kang
  • Marker for predicting gastric cancer prognosis and method for predicting gastric cancer prognosis using the same
    Patent number: 9315869
    Abstract: The present invention relates to a marker for predicting a gastric cancer prognosis, a composition and a kit for predicting gastric cancer prognosis comprising an agent for measuring the expression level thereof, and a method for predicting gastric cancer prognosis using the marker. According to the present invention, gastric cancer prognosis may be predicted promptly and accurately, and an appropriate treatment plan can be determined based on the predicted prognosis, which has an advantage of contributing to significant reduction of death caused by gastric cancer. Particularly, according to the present invention, the survival rate can be remarkably increased by using the treatment method for a stage III gastric cancer patient to a patient who has been predicted to have a negative prognosis among stage Ib/II gastric cancer patients.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: April 19, 2016
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Soon Myung Paik, Sung Kim, Won Ki Kang, Jee Yun Lee, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh, Min Gew Choi, Young Suk Park, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, Sin Ho Jung
  • MARKER FOR PREDICTING GASTRIC CANCER PROGNOSIS AND METHOD FOR PREDICTING GASTRIC CANCER PROGNOSIS USING THE SAME
    Publication number: 20130337449
    Abstract: The present invention relates to a marker for predicting a gastric cancer prognosis, a composition and a kit for predicting gastric cancer prognosis comprising an agent for measuring the expression level thereof, and a method for predicting gastric cancer prognosis using the marker. According to the present invention, gastric cancer prognosis may be predicted promptly and accurately, and an appropriate treatment plan can be determined based on the predicted prognosis, which has an advantage of contributing to significant reduction of death caused by gastric cancer. Particularly, according to the present invention, the survival rate can be remarkably increased by using the treatment method for a stage III gastric cancer patient to a patient who has been predicted to have a negative prognosis among stage Ib/II gastric cancer patients.
    Type: Application
    Filed: December 13, 2011
    Publication date: December 19, 2013
    Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Soon Myung Paik, Sung Kim, Won Ki Kang, Jee Yun Lee, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh, Min Gew Choi, Young Suk Park, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, Sin Ho Jung
  • Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
    Patent number: 6040334
    Abstract: Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: March 21, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Charles Myers, Jane Trepel, Won Ki Kang, Luke Whitesell, Len Neckers